January 3, 2024 09:25 AM ESTUpdated January 4, 07:17 AM

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

HAYWARD, Calif. — After two decades at the highest R&D ranks of pharma, Roger Perlmutter has a blunt explanation for why drug development so often goes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study